STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:STOK

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/02/27	06:30	Business Wire	Stoke Therapeutics to Present at Upcoming Investor Conferences in March	NASDAQ:STOK	Stoke Therapeutics Inc
2025/02/19	06:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STOK	Stoke Therapeutics Inc
2025/02/18	22:00	Business Wire	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments	NASDAQ:STOK	Stoke Therapeutics Inc
2025/02/18	22:00	GlobeNewswire Inc.	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments	NASDAQ:STOK	Stoke Therapeutics Inc
2025/01/09	06:30	Business Wire	Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:STOK	Stoke Therapeutics Inc
2025/01/07	21:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STOK	Stoke Therapeutics Inc
2025/01/07	21:00	Business Wire	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome	NASDAQ:STOK	Stoke Therapeutics Inc
2025/01/07	06:30	Business Wire	Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/28	07:23	Edgar (US Regulatory)	Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/28	07:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/24	08:15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/12	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/12	06:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/11	09:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/11	09:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/10	06:48	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/07	07:19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/07	02:00	Business Wire	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/06	06:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/06	06:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/04	21:00	Business Wire	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/04	06:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/04	06:11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/12/02	22:00	Business Wire	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/14	23:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/06	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/06	06:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/05	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/05	21:00	Business Wire	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates	NASDAQ:STOK	Stoke Therapeutics Inc
2024/11/02	05:50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:STOK	Stoke Therapeutics Inc